Ionis Pharmaceuticals, Inc.
Common Stock · USD · NASDAQ
Price
$77.63
Cap
—
Earnings
—
30d Trend
+8.6%
29% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 51×Macro 0.99 (−1%)=50
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate Ionis Pharmaceuticals, Inc. at 50/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 67/100. I classify this as a growth position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+3.3%
3 MONTHS
-4.7%
12 MONTHS
+131.1%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Limited short-term thesis. Momentum (67) and low-risk profile are the primary strengths. I note that quality is the weakest area at 29/100 — this warrants monitoring. Historical volatility is moderate at 29%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.